Episode 580: How ImmunoPrecise Antibodies ($IPA) Uses AI to Transform Antibody-Based Drug Discovery

What happens when decades of lab expertise meet cutting-edge AI? In this interview, Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), talks about how her team is using advanced science and artificial intelligence to develop safer, faster, and more effective antibody-based medicines. With over 3,000 antibody discovery programs completed, they are transforming the future of drug discovery—cutting time, costs, and risks in the development process. Discover how decades of hands-on lab experience and innovative AI tools are helping identify the best drug candidates faster than ever before. Learn more about ImmunoPrecise Antibodies: https://www.ipatherapeutics.com/ Watch the full YouTube interview here: https://youtu.be/mE9mDa7uGTs And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1